NHS patients could receive cutting-edge treatments months earlier under new pilot programmes designed to accelerate access to innovative medicines while reshaping how new therapies are priced, approved and rolled out across the health service.
The initiatives, developed by a joint taskforce involving the Department of Health and Social Care, industry partners and the NHS, aim to speed up adoption of new treatments while maintaining value for money for taxpayers. Patient groups also contributed through a 10-week rapid “sprint” process.
The pilots, which will begin testing as early as September, are intended to remove delays in getting approved medicines to eligible patients—particularly those with rare or life-limiting conditions.
One strand will focus on ensuring treatments that have already passed safety, quality and clinical standards can reach patients faster, including therapies for rare diseases where time is critical.
The announcement builds on changes to the National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold introduced in April 2026. Since then, nine additional medicines have already been approved for use in England and Wales, covering conditions including blood disorders, autoimmune diseases and cancers such as brain tumours in children and advanced stomach cancer.
Collectively, officials say these approvals could benefit thousands of patients who previously had limited or no treatment options.
Health and Social Care Secretary James Murray said: "When a new medicine is proven to work, patients shouldn’t have to wait. These pilots are designed to give life-changing treatments to NHS patients faster and more fairly than ever before, while ensuring taxpayers continue to get value for money. That’s good for patients, good for the NHS and good for Britain’s place as a world leader in life sciences."
Other measures under the pilot programme include new ways to recognise the economic benefits of medicines, such as enabling patients to return to work sooner, and industry co-investment models to support screening, testing and patient care pathways. Regional funding schemes are also planned to speed up local adoption of priority treatments.
The reforms align with commitments made under the UK-US pharmaceutical arrangement, which aims to double spending on innovative medicines from 0.3% to 0.6% of GDP over the next decade.
Science Minister Lord Vallance said: "We are in an era of rapid advances in new preventative measures, treatments and even cures. We have a responsibility to get the most important of these into the hands of doctors and patients as quickly as possible. These pilots will help us do exactly that."
Industry leaders welcomed the move. Association of the British Pharmaceutical Industry Chief Executive Richard Torbett said the programme reflects “intensive and focused effort” between government and industry to improve access and strengthen investment conditions in the UK life sciences sector.
Patient and charity groups also backed the changes. Dr Scott Purdon of the Charity Medicines Access Coalition said the pilots could make a real difference for people with life-limiting conditions, where delays can directly affect survival and quality of life.
Nick Meade of Genetic Alliance UK highlighted the urgency for rare disease patients, noting that many conditions have no effective treatments and that earlier access could be life-changing.
